Calithera Biosciences, Inc. CALA
0.00 USD 0.00 (+0.00%)
At closeNov 2, 2026, 4:00 PM EST
0.0001 Day range 0.0001
0.0001 52-week range 0.001
- YTD
- 0.00%
- 1 year
- -50.00%
Analyst view
Consensus: hold
Hold
Price target (mean) 5.00 +4999900.0% upside
Now 0.0001
- Target (low)
- 2.00
- Target (mean)
- 5.00
- Target (high)
- 8.00
Ratings (0m) 5 4 buy · 1 hold · 0 sell
- Strong buy3
- Buy1
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 1
- 2 months ago 3
- 3 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.49 | -1.49 – -1.49 | -4.80 | +69.0% | 0 | 0.0% | 1 |
| Next quarter | -0.52 | -0.52 – -0.52 | -3.60 | +85.6% | 0 | 0.0% | 1 |
| Current year | -8.62 | -8.62 – -8.62 | -17.40 | +50.5% | 0 | 0.0% | 1 |
| Next year | -1.35 | -1.35 – -1.35 | -8.62 | +84.3% | 0 | 0.0% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2022 | Ladenburg Thalmann | Downgrade | Buy | Neutral |
| Nov 15, 2022 | SVB Leerink | Downgrade | Outperform | Market Perform |
| Aug 29, 2022 | HC Wainwright & Co. | Upgrade | Neutral | Buy |
| Aug 16, 2022 | SVB Leerink | Maintained | — | Outperform |
| May 11, 2022 | Wells Fargo | Maintained | — | Equal-Weight |
| Apr 4, 2022 | SVB Leerink | Maintained | — | Outperform |
| Jan 31, 2022 | Ladenburg Thalmann | Initiated | — | Buy |
| Jan 20, 2022 | SVB Leerink | Upgrade | Market Perform | Outperform |
| Nov 8, 2021 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Nov 5, 2021 | William Blair | Downgrade | Outperform | Market Perform |
| Jan 5, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Jan 5, 2021 | SVB Leerink | Downgrade | Outperform | Market Perform |
| Aug 11, 2020 | SVB Leerink | Maintained | — | Outperform |
| May 8, 2020 | HC Wainwright & Co. | Reiterated | — | Buy |
| Mar 27, 2020 | Citigroup | Maintained | — | Buy |
| Mar 27, 2020 | Jefferies | Initiated | — | Buy |
| Nov 19, 2019 | H.C. Wainwright | Initiated | — | Buy |
| Feb 16, 2018 | Citigroup | Upgrade | Neutral | Buy |
| Oct 5, 2017 | William Blair | Initiated | — | Outperform |
| Mar 28, 2017 | H.C. Wainwright | Maintained | — | Buy |
| Jan 24, 2017 | Citigroup | Upgrade | Sell | Neutral |
| Oct 25, 2016 | Citigroup | Initiated | — | Sell |
| Mar 9, 2016 | JMP Securities | Maintained | — | Market Outperform |
| Jul 24, 2015 | Citigroup | Initiated | — | Buy |
| Jan 28, 2015 | Citigroup | Maintained | — | Buy |
| Oct 27, 2014 | Citigroup | Initiated | — | Buy |
| Oct 27, 2014 | Wells Fargo | Initiated | — | Outperform |
| Oct 27, 2014 | Leerink Swann | Initiated | — | Outperform |